Patents Assigned to D. Collen Research Foundation
-
Patent number: 7582296Abstract: The present invention discloses anti-idiotypic antibodies and fragments thereof against inhibitory Factor VIII anti-bodies, said inhibitory antibodies having an affinity for the C2 domain of Factor VIII. The anti-idiotypic antibodies of the present invention are able to completely neutralise in vitro and in an in vivo mouse model the inhibitory activity of FVIII inhibitors. The anti idiotypic antibodies of the present invention can be applied for the prevention, treatment or reduction of bleeding disorders of hemophilia patients with inhibitory antibody against the C2 domain of Factor VIII.Type: GrantFiled: July 28, 2003Date of Patent: September 1, 2009Assignee: D. Collen Research Foundation VZWInventors: Jean Guy G. Gilles, Jean-Marie R. Saint-Remy, Marc G. Jacquemin
-
Publication number: 20080279906Abstract: The present invention relates to the treatment of motoneuron diseases. More particularly the invention relates to the treatment of amyotrophic lateral sclerosis (ALS). It is found that the intracerebroventricular delivery of low amounts of vascular endothelial growth factor into a preclinical ALS animal model induces a significant motor performance and prolongation of survival time of said animals.Type: ApplicationFiled: May 27, 2005Publication date: November 13, 2008Applicants: Vlaams Interuniversitair Instituut Voor Biotechnologie VZW, D. Collen Research Foundation vzwInventor: Peter Carmeliet
-
Patent number: 7357929Abstract: This invention relates to antagonists of placental growth factor and signalling thereof, pharmaceutical compositions containing such antagonists and the use of such antagonists to prevent bone loss or bone mass and to enhance bone healing including the treatment of conditions which present with low bone mass and/or bone defects in vertebrates, and particularly mammals, including humans.Type: GrantFiled: June 27, 2003Date of Patent: April 15, 2008Assignees: D. Collen Research Foundation VZW, K.U. Leuven Research & Development, Vlaams Interuniversitair Instituut Voor Biotechnologie VZWInventors: Peter Carmeliet, Désiré Collen, Roger Bouillon, Gertrudis Carmeliet
-
Patent number: 7341992Abstract: The in vivo role of the N-terminal lectin-like domain of thrombomodulin was studied by using homologous recombination in murine ES cells to create mutant mice that lack this region of thrombomodulin. Phenotypic analysis shows that said mice respond identically to their wild type littermates following pro-coagulant challenges meaning that the protein C pathway is not altered by the mutation. However, following several inflammatory stimuli, it was observed that the mutant mice showed an elevated neutrophil extravasation in several organs. It is found that leukocyte adhesion could be abrogated by addition of recombinant lectin-domain meaning that said domain has direct anti-inflammatory properties which means that the lectin-like domain can be used to manufacture a medicament useful for the treatment of a variety of inflammatory disease processes.Type: GrantFiled: May 24, 2002Date of Patent: March 11, 2008Assignees: Vlaams Interuniversitair Instituut Voor Biotechnologie VZW, D. Collen Research FoundationInventors: Edward M. Conway, Désiré Collen
-
Publication number: 20060292149Abstract: The present invention discloses inhibitory antibodies against Factor VIII with modified glycosylation, either by enzymatic deglycosylation or by site directed mutagenesis. Said antibodies with modified glycosylation have equal affinity for FVIII but show different inhibiting properties. The use of one or a mixture of said antibodies allow modulation of the inhibition of factor VII to levels between 40 and 95%. The present invention further disclosed pharmaceutical compositions comprising inhibitory antibodies against Factor VIII with modified glycosylation, combinations of these antibodies and methods for treating haemostasis disorders using said antibodies and antibody mixtures.Type: ApplicationFiled: August 16, 2004Publication date: December 28, 2006Applicant: D. COLLEN RESEARCH FOUNDATION VZWInventors: Jean-Marie Saint-Remy, Marc Jacquemin
-
Publication number: 20060239998Abstract: The present invention discloses anti-idiotypic antibodies and fragments thereof against inhibitory Factor VIII anti-bodies, said inhibitory antibodies having an affinity for the C2 domain of Factor VIII. The anti-idiotypic antibodies of the present invention are able to completely neutralise in vitro and in an in vivo mouse model the inhibitory activity of FVIII inhibitors. The anti idiotypic antibodies of the present invention can be applied for the prevention, treatment or reduction of bleeding disorders of hemophilia patients with inhibitory antibody against the C2 domain of Factor VIII.Type: ApplicationFiled: July 28, 2003Publication date: October 26, 2006Applicant: D. COLLEN RESEARCH FOUNDATION VZWInventors: Jean Guy Gilles, Jean-Marie Saint-Remy, Marc Jacquemin
-
Publication number: 20060210532Abstract: Described are methods of modulating stem/progenitor cell recruitment involving molecules that agonize the formation of plasmin stimulating the recruitment of stem/progenitor cells, including hematopoietic and endothelial precursor cells. Conversely, antagonists of plasmin can inhibit recruitment of the stem cells. In addition, the identification of the uPA receptor (uPAR) as a retention signal for stem cells in their niche suggests a novel method for increased engraftment and isolation of multipotent stem cells.Type: ApplicationFiled: March 28, 2006Publication date: September 21, 2006Applicants: Vlaams Interuniversitair Instituut Voor Biotechnologie VZW, D. Collen Research Foundation vzwInventors: Peter Carmeliet, Marc Tjwa
-
Patent number: 7105168Abstract: The present invention relates to prevention and treatment of strokes and ischemic diseases and to post-ischemic therapeutic treatment. The invention furthermore relates to the use of a growth factor for treating, more particularly restoring the function of ischemic tissue, in particular muscles such as myocardium and skeletal muscles.Type: GrantFiled: June 4, 2003Date of Patent: September 12, 2006Assignee: D. Collen Research Foundation VZWInventors: Peter Carmeliet, Désiré Collen
-
Patent number: 7067313Abstract: The present invention comprises ligands and methods of manufacture thereof as well as pharmaceutical preparations including the ligands. The ligands may be human or humanized monoclonal antibodies and fragments, derivatives and homologs thereof. These may exhibit an unforeseen “plateau effect”, i.e. the achievement of only a partial inactivation of a factor involved in hemostasis, in particular in the coagulation cascade, either individually or in combination even in molar excess. The ligands may bind to a factor or a complex of factors resulting in only partially impairing the function of a physiologically functional site of the said factor or factor complex even in molar excess. This makes the ligands particularly suitable for treating coagulation disorders and resulting thrombotic pathologic conditions while minimizing the risk of bleeding.Type: GrantFiled: July 13, 2000Date of Patent: June 27, 2006Assignee: D. Collen Research FoundationInventors: Marc G. Jacquemin, Jean-Marie R. Saint-Remy
-
Patent number: 6930089Abstract: Vascular endothelial growth factor, placenta growth factor or combinations of both including heteodimers are useful in the treatment or prevention of stroke or ischemic diseases in mammals.Type: GrantFiled: February 5, 2001Date of Patent: August 16, 2005Assignees: D. Collen Research Foundation vzw, Flanders Interuniversity Institute for Biotechnology, VIBInventor: Peter Carmeliet